A SARS-CoV-2 spike-derived adjuvant peptide boosts IL-17/IFN-γ immunity and improves anti-PD-L1 therapy against melanoma
Embedding a SARS-derived adjuvant-like motif within a PD-L1 peptide vaccine and delivering it in situ may re-condition the tumor microenvironment toward an immune-activating, Th1/Th17-biased state and complement PD-L1 blockade.
Authors
- Huang Kai-yao
- Shun-Long Weng (ORCID: https://orcid.org/0000-0002-2297-1225)
- Hui-Ju Kao (ORCID: https://orcid.org/0000-0001-6109-0319)
- Hsiao-Hsuan Huang
- C. T. Huang
- Liao Kuang-Wen
- Chia-Hung Chen
- Yu-Chi Chen
- Ta-Wei Kuo
- Tzu-Han Weng
- Chen-Lin Yu
Institutions
- National Yang Ming Chiao Tung University (TW)
- Kaohsiung Medical University (TW)
- Mackay Memorial Hospital (TW)
- Mackay Medical University (TW)
- Mackay Junior College of Medicine, Nursing and Management (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Molecular Medicine
- Published
- 2025-12-27
- DOI
- https://doi.org/10.1186/s10020-025-01384-2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministry of Education, India
- Mackay Memorial Hospital
- National Science and Technology Council